MassDevice.com sat down with Boston Scientific (NYSE:BSX) CFO Jeffrey Capello in New York City this week on the heels of the medical device company’s analyst day to discuss its outlook for 2013 and beyond.
Wall Street Beat
Surgical devices: Misonix swings to the red in Q2
Holaira raises $10M for lung device | Wall Street Beat
Medical device company Holaira said it drummed up $10 million, changed its name and moved its headquarters.
Formerly known as Innovative Pulmonary Solutions, Holaira said it plans to use the Series C round to develop its minimally invasive devices to treat obstructive lung disease. All of Holaira’s existing backers participated, namely Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures.
Stung by widening losses, Accuray plans $75M debt offering | Wall Street Beat
Accuray (NSDQ:ARAY) plans to issue $75 million worth of convertible senior notes as it gears up to restructure its business after a year of widening losses.
The Sunnyvale, Calif.-based medical device company said it will use the proceeds from the offering of debt due Feb. 1, 2018, to shore up its balance sheet.
Abiomed CEO Minogue on DoJ probe, FDA call
Cardiologists aren’t paying much attention to the noise around Abiomed (NSDQ:ABMD) and its flagship medical device, the Impella heart pump, at least according to chairman, president & CEO Michael Minogue.
That noise centered around a pair of events during the 4th quarter: news of a U.S. Justice Dept. probe into its marketing of the Impella pump and an FDA decision to require the device to undergo a more rigorous approval process.
William Blair boosts NxStage stake by 20% | Wall Street Beat
William Blair & Co. added 20% to its holdings in NxStage Medical (NSDQ:NXTM) last year, according to regulatory filings.
The Chicago-based investment bank owned more than 3.8 million NXTM shares as of Dec. 31, 2012, up 19.5% from the 3.2 million shares it owned at the close of 2011.
Echo Therapeutics prices offering | Wall Street Beat
Echo Therapeutics (NSDQ:ECTE) priced its public stock offering at 75¢ per share, saying it expects to raise about $10 million in gross proceeds.
The 13.3 million-share offering includes a 45-day over-allotment option for bookrunner Aegis Capital for another 2 million shares.
Covidien updates on medical device, pharma split
Ivantis reels in $27M Series B round | Wall Street Beat
Ivantis said it raised a $27 million Series B round led by Ascension Health Ventures aimed at funding a quartet of clinical trials for its Hydrus Microstent glaucoma treatment.
The Irvine, Calif.-based medical device company said the device, an eyelash-sized stent, is designed to reduce eye pressure.
Boston Scientific hits 52-week high
Boston Scientific (NYSE:BSX) shares hit a 52-week high 2 days ago and are flirting with another today, as investors react to strong 4th-quarter and 2012 results.
The Marlborough, Mass.-based medical device company’s stock hit $7.43 per share Jan. 29, the day it announced its financial numbers. Shares had fallen as low as $4.79 apiece during the last 52 weeks.
Align beats The Street and rises on record 2012 sales
Orthodontic devices maker Align Technology (NSDQ:ALGN) won big points on Wall Street today after releasing a strong 4th quarter earnings report, beating expectations and issuing optimistic projections for 2013.